Literature DB >> 28236043

Cystic fibrosis in Austria.

Thomas Frischer1, Ernst Eber2, Helmut Ellemunter3, Angela Zacharasiewicz4, Ingrid Kaluza5, Josef Riedler6, Sabine Renner7.   

Abstract

Registry data for patients with cystic fibrosis (CF) are increasingly used to evaluate the natural history, for benchmarking of therapy and in order to identify eligible patients for clinical studies. So far, no data on frequency and clinical status of CF patients have been available for Austria on a national level. We collected data of CF patients treated 2014 in Austrian CF outpatient clinics by means of a European CF registry and on an individual search basis. A total of 773 CF patients with a median age of 18.9 years (SD 11.8 years) were seen in 13 centers (18-151 patients/center). Homozygous F508del mutation being the most common genotype was observed in 48.8% of patients. Mean age at diagnosis was 27 days. In 59% of all patients FEV1% predicted (Forced Exspiratory Volume in 1 second) was <80% and in 20% <50%. An average FEV1 predicted decline per year of 1.9% was observed between 6-18 years of age. Colonisation with Pseudomonas aeruginosa ranged between 12% and 69% in adult patients and in 0-16% in children with CF. Burkholderia cepacia complex species were present in a total of 29 samples (3.8%). Insulin therapy for diabetes was given in 14.5%. Liver involvement was reported in 36.3%. A wide variation of prescribed CF therapy was observed between centers. Data on CF patients living in Austria are now available and form a basis for clinical benchmarking as well as analyses from a public health perspective.

Entities:  

Keywords:  Cystic fibrosis; Epidemiology; Patient registry

Mesh:

Substances:

Year:  2017        PMID: 28236043     DOI: 10.1007/s00508-017-1179-x

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  8 in total

Review 1.  Translating the genetics of cystic fibrosis to personalized medicine.

Authors:  Harriet Corvol; Kristin E Thompson; Olivier Tabary; Philippe le Rouzic; Loïc Guillot
Journal:  Transl Res       Date:  2015-04-15       Impact factor: 7.012

2.  Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report.

Authors:  T Pressler; C Bohmova; S Conway; S Dumcius; L Hjelte; N Høiby; H Kollberg; B Tümmler; V Vavrova
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

3.  Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

Authors:  A Equi; I M Balfour-Lynn; A Bush; M Rosenthal
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

4.  Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

Authors:  Maurizio Renna; Catherine Schaffner; Karen Brown; Shaobin Shang; Marcela Henao Tamayo; Krisztina Hegyi; Neil J Grimsey; David Cusens; Sarah Coulter; Jason Cooper; Anne R Bowden; Sandra M Newton; Beate Kampmann; Jennifer Helm; Andrew Jones; Charles S Haworth; Randall J Basaraba; Mary Ann DeGroote; Diane J Ordway; David C Rubinsztein; R Andres Floto
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

5.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

6.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

Review 7.  An overview of international literature from cystic fibrosis registries. Part 4: update 2011.

Authors:  Donatello Salvatore; Roberto Buzzetti; Ermanno Baldo; Maria Lucia Furnari; Vincenzina Lucidi; Daniela Manunza; Italo Marinelli; Barbara Messore; Anna Silvia Neri; Valeria Raia; Gianni Mastella
Journal:  J Cyst Fibros       Date:  2012-08-09       Impact factor: 5.482

8.  Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis.

Authors:  Alison M Binder; Jennifer Adjemian; Kenneth N Olivier; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2013-10-01       Impact factor: 21.405

  8 in total
  2 in total

1.  Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier Parameters.

Authors:  Maximilian Zeyda; Andrea Schanzer; Pavel Basek; Vera Bauer; Ernst Eber; Helmut Ellemunter; Margit Kallinger; Josef Riedler; Christina Thir; Franz Wadlegger; Angela Zacharasiewicz; Sabine Renner
Journal:  Diagnostics (Basel)       Date:  2021-02-13

2.  Managing Cystic Fibrosis in Polish Healthcare.

Authors:  Marta Rachel; Stanisław Topolewicz; Andrzej Śliwczyński; Sabina Galiniak
Journal:  Int J Environ Res Public Health       Date:  2020-10-20       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.